Proxima is pioneering a transformative approach to drug discovery by illuminating the dynamic networks of protein interactions that drive biological function. Leveraging a groundbreaking structural proteomics platform and frontier machine learning capabilities, Proxima is uniquely positioned to unlock novel therapeutic strategies that induce, modulate, or block protein interfaces, making previously undruggable targets accessible and providing powerful new ways to target diseases by rewiring cellular circuitry. Alongside a robust and mechanistically differentiated internal pipeline, Proxima collaborates extensively with external partners to accelerate the discovery and development of innovative therapies across novel proximity modalities.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/15/26 | $80,000,000 | Seed |
AIX Ventures Alexandria Venture Investments Braidwell DCVC  Magnetic Ventures Modi Ventures NVentures Roivant Health Yosemite | undisclosed |
